Edge Rewrite
// HTMLRewriter · presentation

This page was redesigned at the edge.

Cloudflare fetched the original article and streamed it through HTMLRewriter to apply an entirely new visual system without rebuilding the source page.

// request.cf · coarse context

A page that knows where it met you.

Only coarse request metadata is shown. This demo does not display or persist visitor IP addresses.

Country
US
Cloudflare location
CMH
Connection
HTTP/2
Language
Not provided

Ray ID: a23ff63a0d98b6ed

Jump to content

// Workers AI · dad joke modeWhat did NJK14047 say to NJK14048? Nothing, it was a number cruncher.

From Wikipedia, the free encyclopedia

NJK14047
Identifiers
  • N-cyclopropyl-3-[4-[4-(2,3-dihydroxypropoxy)benzoyl]phenyl]-4-methylbenzamide
CAS Number
PubChem CID
ChemSpider
Chemical and physical data
FormulaC27H27NO5
Molar mass445.515 g·mol−1
3D model (JSmol)
  • CC1=C(C=C(C=C1)C(=O)NC2CC2)C3=CC=C(C=C3)C(=O)C4=CC=C(C=C4)OCC(CO)O
  • InChI=1S/C27H27NO5/c1-17-2-3-21(27(32)28-22-10-11-22)14-25(17)18-4-6-19(7-5-18)26(31)20-8-12-24(13-9-20)33-16-23(30)15-29/h2-9,12-14,22-23,29-30H,10-11,15-16H2,1H3,(H,28,32)
  • Key:ZQIUCYZGBDPMLG-UHFFFAOYSA-N

NJK14047 is a drug which acts as a selective inhibitor of the enzyme p38 mitogen-activated protein kinase (p38 MAPK). It has antiviral and antiinflammatory effects and was originally developed as a potential treatment for inflammatory lung conditions such as influenza. Subsequent research has also shown promise for various other conditions in which inflammation plays a role, including Alzheimer's disease, asthma, arthritis and psoriasis.[1][2][3][4]

See also

[edit]

References

[edit]
  1. Choi MS, Heo J, Yi CM, Ban J, Lee NJ, Lee NR, et al. (August 2016). "A novel p38 mitogen activated protein kinase (MAPK) specific inhibitor suppresses respiratory syncytial virus and influenza A virus replication by inhibiting virus-induced p38 MAPK activation". Biochemical and Biophysical Research Communications. 477 (3): 311–316. doi:10.1016/j.bbrc.2016.06.111. PMID 27346133.
  2. Gee MS, Son SH, Jeon SH, Do J, Kim N, Ju YJ, et al. (April 2020). "A selective p38α/β MAPK inhibitor alleviates neuropathology and cognitive impairment, and modulates microglia function in 5XFAD mouse". Alzheimer's Research & Therapy. 12 (1): 45. doi:10.1186/s13195-020-00617-2. PMC 7175487. PMID 32317025.
  3. Lee JH, Son SH, Kim NJ, Im DS (March 2023). "NJK14047 Suppression of the p38 MAPK Ameliorates OVA-Induced Allergic Asthma during Sensitization and Challenge Periods". Biomolecules & Therapeutics. 31 (2): 183–192. doi:10.4062/biomolther.2022.078. PMC 9970832. PMID 36171179.
  4. Lee JH, Lee JE, Son SE, Son SH, Kim NJ, Im DS (March 2024). "NJK14047 inhibition of p38 MAPK ameliorates inflammatory immune diseases by suppressing T cell differentiation". International Immunopharmacology. 130 111800. doi:10.1016/j.intimp.2024.111800. PMID 38447416.